Initial Treatment for Extrapulmonary Sarcoidosis

Introduction to Treatment

• The European Respiratory Society recommends oral prednisone at 20-40 mg daily for 3-6 months as the first-line treatment for symptomatic extrapulmonary sarcoidosis, followed by gradual tapering to the lowest effective dose 1, 2, 3

When to Initiate Treatment

• Treatment is indicated when extrapulmonary sarcoidosis meets any of these criteria: high risk for mortality or permanent organ disability, significant impairment of quality of life from symptoms 1, 2
• The European Respiratory Society suggests not treating patients without symptoms, organ dysfunction risk, or quality of life impairment due to high prevalence of glucocorticoid adverse events 2

First-Line Treatment Protocol

• Start prednisone 20-40 mg daily for symptomatic disease with organ dysfunction risk 1, 3
• For quality of life impairment alone without organ threat, consider lower initial dose of 5-10 mg daily through shared decision-making 2
• Continue initial dose for 3-6 months to assess therapeutic response 4, 3

Dose Modifications for Comorbidities

• Reduce the starting dose in patients with diabetes, psychosis, or osteoporosis 3, 4

Monitoring and Tapering

• Evaluate response at 3 months with clinical assessment, organ-specific testing, and imaging 5
• If improved, begin tapering to the lowest dose maintaining symptom control and disease stability 4, 3
• Target total treatment duration of 6-18 months from initiation if disease responds 3, 5

When to Add Second-Line Therapy

• Add methotrexate 10-15 mg weekly if disease progression despite adequate glucocorticoid treatment, unacceptable glucocorticoid side effects, or unable to taper prednisone below 10 mg daily after 6 months 1, 2, 3
• Methotrexate is the preferred second-line agent based on the most extensive evidence and best tolerability profile 4, 3

Third-Line Treatment

• Add infliximab for patients with continued disease despite glucocorticoids and methotrexate, particularly for severe extrapulmonary manifestations including cardiac and neurologic sarcoidosis 2, 3

Organ-Specific Considerations

• Cardiac MRI is suggested for suspected cardiac involvement 6
• Baseline serum calcium testing is strongly recommended to screen for abnormal calcium metabolism 6

Common Pitfalls to Avoid

• Do not use inhaled corticosteroids as adjunctive therapy - three randomized trials showed no benefit when added to oral glucocorticoids 1
• Avoid prolonged prednisone monotherapy ≥10 mg daily - even low doses cause significant toxicity including weight gain, metabolic complications, and reduced quality of life 3, 5
• Do not continue ineffective treatment - lack of response over 3-6 months indicates need for alternative strategy 4, 7

Managing Disease Changes During Treatment

• If disease worsens, add or increase adjunctive therapy (methotrexate) and re-evaluate diagnosis and treatment plan 4
• If disease improves, decrease steroid dose gradually to lowest effective level 4, 3

Relapse Management

• If relapse occurs during or after tapering, restart prednisone at the last effective dose and add methotrexate as steroid-sparing agent 5

Supportive Care During Glucocorticoid Therapy

• Provide prophylaxis during prolonged steroid use, including calcium and vitamin D supplementation 5, 6